Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review …
Context Randomized clinical trials have recently examined the benefit of adding docetaxel
or abiraterone to androgen deprivation therapy (ADT) in hormone-naïve advanced prostate …
or abiraterone to androgen deprivation therapy (ADT) in hormone-naïve advanced prostate …
Molecular and cellular mechanisms of castration resistant prostate cancer
Y Huang, X Jiang, X Liang, G Jiang - Oncology letters, 2018 - spandidos-publications.com
With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa,
particularly the advanced and metastatic disease, has been the focus of a number of studies …
particularly the advanced and metastatic disease, has been the focus of a number of studies …
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth
Abstract Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme
that mainly represses transcription of target genes via symmetric dimethylation of arginine …
that mainly represses transcription of target genes via symmetric dimethylation of arginine …
Ginger phytochemicals inhibit cell growth and modulate drug resistance factors in docetaxel resistant prostate cancer cell
CM Liu, CL Kao, YT Tseng, YC Lo, CY Chen - Molecules, 2017 - mdpi.com
Ginger has many bioactive compounds with pharmacological activities. However, few
studies are known about these bioactive compounds activity in chemoresistant cells. The …
studies are known about these bioactive compounds activity in chemoresistant cells. The …
Nonmetastatic castration-resistant prostate cancer: current challenges and trends
A Figueiredo, L Costa, MJ Maurício, L Figueira… - Clinical Drug …, 2022 - Springer
Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …
generally associated with a consistent elevation of prostate-specific antigen levels …
ABCB1 mediates cabazitaxel–docetaxel cross-resistance in advanced prostate cancer
AP Lombard, C Liu, CM Armstrong, V Cucchiara… - Molecular cancer …, 2017 - AACR
Advancements in research have added several new therapies for castration-resistant
prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC …
prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC …
Natural product-based studies for the management of castration-resistant prostate cancer: Computational to clinical studies
Background: With prostate cancer being the fifth-greatest cause of cancer mortality in 2020,
there is a dire need to expand the available treatment options. Castration-resistant prostate …
there is a dire need to expand the available treatment options. Castration-resistant prostate …
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration …
N Plouznikoff, C Artigas, S Sideris… - Annals of nuclear …, 2019 - Springer
Objective To investigate the association between Prostate-Specific Membrane Antigen
(PSMA) expression changes on positron emission tomography–computed tomography …
(PSMA) expression changes on positron emission tomography–computed tomography …
mTOR inhibitors in castration-resistant prostate cancer: a systematic review
CM Statz, SE Patterson, SM Mockus - Targeted oncology, 2017 - Springer
Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …
[HTML][HTML] Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo
G Lv, D Sun, J Zhang, X Xie, X Wu, W Fang… - … Pharmaceutica Sinica B, 2017 - Elsevier
Tubulin has been shown to be an effective target for the development of cytotoxic agents
against prostate cancer. Previously, we reported that Lx2-32c is an anti-tubulin agent with …
against prostate cancer. Previously, we reported that Lx2-32c is an anti-tubulin agent with …